Market closed
TG Therapeutics/$TGTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About TG Therapeutics
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
Ticker
$TGTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
338
Website
TG Therapeutics Metrics
BasicAdvanced
$6B
275.53
$0.15
2.14
-
Price and volume
Market cap
$6B
Beta
2.14
52-week high
$43.32
52-week low
$12.93
Average daily volume
2.7M
Financial strength
Current ratio
6.246
Quick ratio
4.854
Long term debt to equity
113.58
Total debt to equity
114.398
Interest coverage (TTM)
1.75%
Management effectiveness
Return on assets (TTM)
5.78%
Return on equity (TTM)
12.21%
Valuation
Price to earnings (TTM)
275.533
Price to revenue (TTM)
18.255
Price to book
26.76
Price to tangible book (TTM)
26.76
Price to free cash flow (TTM)
-148.069
Growth
Revenue change (TTM)
40.80%
Earnings per share change (TTM)
68.04%
3-year revenue growth (CAGR)
266.39%
3-year earnings per share growth (CAGR)
-61.52%
What the Analysts think about TG Therapeutics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for TG Therapeutics stock.
TG Therapeutics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
TG Therapeutics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
TG Therapeutics News
AllArticlesVideos
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
GlobeNewsWire·3 weeks ago
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
GlobeNewsWire·3 weeks ago
TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for TG Therapeutics stock?
TG Therapeutics (TGTX) has a market cap of $6B as of April 28, 2025.
What is the P/E ratio for TG Therapeutics stock?
The price to earnings (P/E) ratio for TG Therapeutics (TGTX) stock is 275.53 as of April 28, 2025.
Does TG Therapeutics stock pay dividends?
No, TG Therapeutics (TGTX) stock does not pay dividends to its shareholders as of April 28, 2025.
When is the next TG Therapeutics dividend payment date?
TG Therapeutics (TGTX) stock does not pay dividends to its shareholders.
What is the beta indicator for TG Therapeutics?
TG Therapeutics (TGTX) has a beta rating of 2.14. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.